title: Topoisomerase I in Human Disease Pathogenesis and Treatments.
abstract: Mammalian topoisomerase 1 (TOP1) is an essential enzyme for normal development. TOP1 relaxes supercoiled DNA to remove helical constraints that can otherwise hinder DNA replication and transcription and thus block cell growth. Unfortunately, this exact activity can covalently trap TOP1 on the DNA that could lead to cell death or mutagenesis, a precursor for tumorigenesis. It is therefore important for cells to find a proper balance between the utilization of the TOP1 catalytic activity to maintain DNA topology and the risk of accumulating the toxic DNA damages due to TOP1 trapping that prevents normal cell growth. In an apparent contradiction to the negative attribute of the TOP1 activity to genome stability, the detrimental effect of the TOP1-induced DNA lesions on cell survival has made this enzyme a prime target for cancer therapies to kill fast-growing cancer cells. In addition, cumulative evidence supports a direct role of TOP1 in promoting transcriptional progression independent of its topoisomerase activity. The involvement of TOP1 in transcriptional regulation has recently become a focus in developing potential new treatments for a subtype of autism spectrum disorders. Clearly, the impact of TOP1 on human health is multifold. In this review, we will summarize our current understandings on how TOP1 contributes to human diseases and how its activity is targeted for disease treatments.
authors.affiliation: Department of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope, Duarte, CA 91010-3000, USA.
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope, Duarte, CA 91010-3000, USA. Electronic address: yiliu@coh.org.
authors.forename: Yilun
authors.initials: Y
authors.lastname: Liu
mesh_terms: D000067877:Autism Spectrum Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D004260:DNA Repair; D004261:DNA Replication; D004264:DNA Topoisomerases, Type I / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D042822:Genomic Instability; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011499:Protein Processing, Post-Translational; D059004:Topoisomerase I Inhibitors / Q000627:therapeutic use*
chemical_list: D059004:Topoisomerase I Inhibitors; D004264:DNA Topoisomerases, Type I
keywords: Autism; Cancer; DNA replication; Scleroderma; Topoisomerase 1; Transcription